Healthcare Industry Insights

Friday, 5 May 2023

Neurological Biomarkers Market Growth, Opportunities and Forecast To 2028 | Abbott; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Merck & Co., Inc.

The global Neurological Biomarkers Market size is expected to reach USD 16.14 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 12.9% from 2020 to 2028. Increasing funding for the R&D of neurological biomarkers to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products for the diagnosis of neurological biomarkers is expected to propel market growth over the forecast period.

The National Institute of Neurological Disorders and Stroke provides funding, such as development grants & cooperative agreements for researchers conducting studies related to biomarker discovery, analytical validation, & clinical validation. Thus, the presence of organizations offering funds at various stages of research is anticipated to drive market growth. For instance, the University of North Texas Health Science Center (HSC) was awarded around USD 45.5 million funds from the National Institutes of Health (NIH) to support research regarding health disparities in Alzheimer’s and brain aging. NIH is offering additional funds for biomarkers research for the ongoing Health and Aging Brain Among Latino Elders (HABLE) study.

Increasing product launches are also expected to drive market growth. For instance, in January 2021, Abbott received FDA 510K clearance for its rapid handheld traumatic brain injury test that measures UCH-L1 and GFAP biomarkers. The results of this test are available within 15 minutes, and it helps clinicians assess the need to perform a CT scan. The rapid turnaround time of this test will help physicians plan and deliver treatment on time.

In August 2018, Olink Proteomics AB introduced a new biomarker panel Olink NEURO EXPLORATORY for the expansion of a portfolio of high-quality protein assays. This product includes a high-performance assay for neurofilament light polypeptide, a significant biomarker for traumatic brain injury and degenerative neurological diseases.

However, the lack of reimbursement coverage for the biomarkers impedes the market growth. Currently, only certain, restricted forms of biomarker tests for dementia symptoms are covered by Medicare and other health insurance programs and their use must be justified based on the symptoms and specific requirements of the individual.

The reimbursement for Alzheimer’s disease is also not provided by most of the insurance providers, such as the Blue Cross and Blue Shield Association. The reimbursement coverage for neurological biomarker testing in developing countries, such as India and China, is even lesser, as these countries have low insurance penetration and very little awareness about biomarker testing.

Related Press Release@ Neurological Biomarkers Market Report

Neurological Biomarkers Market Report Highlights

Increasing collaborations and public-private partnerships for research initiatives may fuel market growth
For instance, in February 2018, MJFF in collaboration with the NIH and five life-sciences companies provided USD 24 million as a research grant for the development of neurological biomarkers
In 2020, the proteomic biomarkers segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period
The Parkinson’s disease segment led the market in 2020. An increasing number of clinical trials for Parkinson’s disease drugs and the growing prevalence of the disease is expected to drive the segment growth in the years to come
North America was the largest regional market in 2020 owing to the high disease burden, acceptance of biomarkers for diagnostic, prognostics, & drug development purposes, and increase in research funding
Asia Pacific is anticipated to witness the fastest CAGR over the forecast period owing to a rising number of clinical trials being conducted in developing countries, such as India and China, increasing disease burden, and growing need for targeted drugs in the central nervous system

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Wednesday, 3 May 2023

Ambulatory Services Market Growth, Opportunities and Forecast To 2026 | AmSurg Corp.; IntegraMed America, Inc.; Terveystalo; Aspen Healthcare; Medical Facilities Corporation

The global Ambulatory Services Market size is expected to reach USD 4.3 trillion by 2026 registering a CAGR of 6.1%, based on a new report by Grand View Research, Inc. Easy availability of advanced products along with technological developments in surgeries to reduce cost and treatment time is expected to be one of the key factors boosting the global market growth. Other prominent factors driving the industry include rising incidences of chronic diseases and growing geriatric population.

Ambulatory services are likely to witness high growth in the coming years due to increasing number of surgeries and availability of same-day surgeries at low cost with better medical services. In addition, availability of private and public funding across various regions will drive the market further. According to the Healthcare Cost and Utilization Project (HCUP), in 2014, 17.2 million surgeries were performed in Ambulatory Surgical Centers (ASCs) and 22 million surgeries in hospital outpatient settings. In addition, various M&A activities by key participants are anticipated to propel the market.

For instance, in December 2015, Premier Emergency Medical Specialists was acquired by AmSurg. This acquisition helped AmSurg enter the emergency medicine specialty. Technological advancements pertaining to diagnosis and minimally invasive surgeries are likely to reduce complications and help shorten hospital stays, thereby boosting market growth. For instance, in January 2017, Arterys, Inc. received FDA approval to commercialize Arterys Cardio DL, the first technology that uses a cloud-based deep learning algorithm for cardiac imaging.

Related Press Release@ Ambulatory Services Market Report

Ambulatory Services Market Report Highlights

High government expenditure for the development of ambulatory facilities to increase accessibility and reduce treatment costs is expected to propel the market growth
Primary care offices accounted for the largest share of the market in 2018 due to cost-effective treatment and easy accessibility for diagnosis and treatment
Surgical specialty is anticipated to be the fastest-growing segment in the forecast period due to a rise in demand for minimally invasive procedures
In addition, preference for nonsurgical and minimally invasive procedures has led to the growth of plastic surgery centers
According to the American Society of Plastic Surgeons, in 2016, 7.6 million cosmetic procedures were performed on people aged between 40 and 54 years
North America held the largest market share and is expected to retain its dominance during the forecast period due to the availability of advanced diagnostics
APAC is likely to witness significant growth due to rising cases of angle closure glaucoma and myopia and development of emergency care outside traditional hospital settings
Some of the key companies in the market are Surgery Partners; Envision Healthcare; IntegraMed America, Inc.; Symbion, Inc.; Terveystalo; NueHealth; Aspen Healthcare; and Medical Facilities Corporation

Biological Safety Testing Products and Services Market: Industry Demand, Analysis And Future Trends 2026

The global Biological Safety Testing Products And Services Market size is expected to reach a value of USD 6.9 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 12.3% The market is predominantly driven by increasing production of biologics, which is boosting the need for highly efficient biological safety testing tools. Rising disease burden is expected to be a major factor responsible for high production of biologics, thereby contributing to market growth.

Increasing prevalence of lifestyle-associated chronic diseases such as cancer and diabetes is a key factor contributing to rise in drug development and subsequent commercialization. This is expected to increase the need for scrutinizing & ensuring safety of targeted and specialized therapies, evaluating outcomes, and circumventing probable shortcomings. In addition, pharmaceutical and biotechnology companies are increasingly incorporating biological safety testing products and services to produce highly potent and contamination-free biologics to cater to the large number of people suffering from target diseases. Viral safety testing is proving to be one of the primary concerns of most companies as it is a critical component of chemistry, manufacturing, and control of biologics. This is creating growth opportunities in the market.

Laboratory-based contamination is leading to development and refinement of workstations through incorporation of biological safety products and services. Increasing need to work with tissue cultures, maintain sterility of cell lines, and minimize cross-contamination has increased concerns regarding product integrity. Rising intervention by government healthcare organizations to implement good manufacturing practices and subsequent testing & control at every production stage is expected to widen the scope for growth.

Related Press Release@ Biological Safety Testing Products and Services Market Report

Biological Safety Testing Products and Services Market Report Highlights

On the basis of product, reagents and kits accounted for the largest share in 2018 as they are major components that are extensively used in research and clinical laboratories
The instruments segment, on the other hand, is expected to grow at a lucrative CAGR during the forecast period due to rising demand from various clinical and research laboratories
On the basis of application, vaccines & therapeutics segment is expected to grow at a significant CAGR during the forecast period mainly owing to increase in disease outbreaks over the years
Bioburden tests are expected to grow at a lucrative rate during the forecast period owing to their high adoption to determine bioburden limit in a wide range of biologics and medical devices
North America dominated the global biological safety testing products and services market in 2018 owing to high R&D investments in biotechnology and huge chronic disease burden
Asia Pacific is expected to grow at an exponential CAGR during the forecast period owing to increase in healthcare spending
Some of the key players are Charles River Laboratories International, Inc.; Lonza Group AG; MilliporeSigma; SGS SA; Sartorius Stedim BioOutsource Limited; and BSL Bioservice Scientific Laboratories GmbH.

List of Key Players in Biological Safety Testing Products and Services Market

· Charles River Laboratories International, Inc.

· Lonza Group AG

· MilliporeSigma

· SGS SA

· Sartorius Stedim BioOutsource Limited

· BSL Bioservice Scientific Laboratories GmbH

Antisense & RNAi Therapeutics Market Size Worth $1.81 Billion By 2025

The global Antisense & RNAi Therapeutics Market size is expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%, according to a new report by Grand View Research, Inc. Development in biological vectors and nanotechnology and rising external funding to conduct clinical studies pertaining to introduction of novel drug moieties play a vital role in the process of product development and fuel growth in this market.

Multinational healthcare establishments promote awareness and aid in finding novel therapies for treatment of different disorders. Private institutes such as California Institute of Regenerative Medicine and ALS Association that are involved in conducting trials by funding the research institutes and pharmaceutical organizations are expected to fuel sector growth significantly. Moreover, government initiatives for speeding the development of drug delivery platforms in order to reduce the disease burden are attributive for industrial growth.

Antisense & RNAi therapeutics services are applicable in treatment of several range of diseases that target the nucleic acid and affect cell growth cycle. miRNA is attracting considerable interest in its ability to restore gene expression and correct protein production thereby influencing industrial progress. Developments that involve research for utilization of different routes to deliver the desired effect of candidate moiety before its removal from blood are anticipated to fuel sector growth.

However, challenges associated with the drug delivery are expected to impede growth to certain extent. Delivery technologies that enable mitigation of the off-target effects and undesirable immunological stimulation need to be introduced to reduce the effect of restraining factors.

Related Press Release@ Antisense & RNAi Therapeutics Market Report

Antisense & RNAi Therapeutics Market Report Highlights

Antisense RNA was the largest technology segment in 2018 owing to the advantages offered by this technology over the antisense technology
Based on the triggering of the RNA molecules this technology is segmented into siRNA and miRNA
Owing to significant involvement of miRNA in maintaining cell’s identity these are used to provide a deep insight into cancer metastasis
Usage of RNAi therapy to selectively target SNPs in genetic disorders is a major factor expected to provide this segment with a number of potential treatment avenues over the forecast period
siRNA is highly specific and allows induction at advanced stages of cancer growth as compared to chemotherapy, which is attributive for the largest share of oncology applications
Extensive R&D programs carried out in this sector to develop an efficient method for the delivery of RNA silencing therapeutic products is anticipated to propel growth

List of Key Players in Antisense & RNAi Therapeutics Market

· Ionis Pharmaceuticals

· GSK

· Alnylam Pharmaceuticals

· Marina Biosciences

· Sanofi-Genzyme

· Quark Pharmaceuticals

· Gene Signal

· Benitec Biopharma

Tuesday, 2 May 2023

Hip Replacement Implants Market Size Worth $7.8 Billion By 2026

The global Hip Replacement Implants Market size is expected to reach USD 7.8 Billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to expand at exhibiting a CAGR of 4.7% over the forecast period. Growing prevalence of osteoarthritis & osteoporosis are expected to drive growth over the forecast period. In addition, a paradigm shift toward minimally invasive procedures is fueling the market globally. Moreover, favorable reimbursement policy is further propelling growth.

Moreover, individuals aged 60 years and above accounted for 12.3% of the global population in 2015 and this population is expected to reach 21.5% in 2050. Thus, increasing population of those aged 60 years and above is expected to impel growth. Moreover, increasing adoption of minimally invasive surgeries coupled with availability of variety of advanced treatment options is a key factor driving the market.

Related Press Release@ Hip Replacement Implants Market Report

Hip Replacement Implants Market Report Highlights

Increasing demand for minimally invasive surgeries is anticipated to create growth opportunities in the hip replacement implants market.
Increasing number of sports injuries & road traffic accidents are driving demand for total replacement surgeries.
Total hip implants accounted for the largest revenue share as of 2018, owing to technological advancements and growing adoption.
Metal-on-polyethylene (MOP) held the largest share of material segment due to its minimal surgical risk and negligible post-surgery complications.
Hospitals & surgery centers held the largest revenue share of end-use segment due to maximum number of surgeries performed within these facilities.
North America held the dominant share as of 2018, due to supportive government initiatives and presence of large number of industry players.
Asia Pacific is anticipated to witness lucrative growth due to increase in the target population and booming medical tourism.
Some key companies are Zimmer Biomet, Johnson & Johnson, Smith & Nephew Plc., Stryker, and Aesculap Implant Systems LLC.

Glycomics Market Growth, Opportunities and Forecast To 2026 | Danaher; ProZyme; Shimadzu Corporation; Agilent Technologies

The global Glycomics Market size is expected to reach USD 2.4 billion by 2026 registering a CAGR of 14.7%, according to a new report by Grand View Research, Inc.Rising focus on glycomics and proteomics research has led to the growth of this market. Significant investments in this field have also enabled academic researchers to develop new tools. Thus, the field of glycoscience is growing, which is a high impact rendering driver for the market. Glycans are essential in biological processes and research on them helps in understanding the biology more comprehensively, without specializing in glycobiology. According to 2018 BDO Biotech Briefing, the average R&D expenditure of the mid-sized biotech companies increased around 14% from 2016 to 2017.

Growing drug discovery and development is leading to a rise in R&D investments by biotech companies. Thus, the need for glycomics research techniques for conducting comprehensive glycomes study is constantly increasing. Rise in the number of initiatives being undertaken by the government to increase funding for R&D has led to the increased need for glycomics techniques. The Australian government invested around USD 10.4 billion for scientific research activities and innovations for the period 2017-2018. The Irish Government also announced a USD 5.6 billion spending program in 2015, which was aimed at increasing the number of scientific research activities from 25,000 to 40,000.

Such funding initiatives are expected to boost the demand for glycomics research techniques in near future. Key companies are also undertaking extensive R&D initiatives to develop new and technologically advanced products. For instance, in 2018, Shimadzu Corp. collaborated with PREMIER Biosoft, a global company in the field of bioinformatics solutions, with an aim to introduce its LCMS-9030 Quadrupole Time of Flight (Q-TOF) mass spectrometry system for advance glycomics and lipidomics data research analysis. In addition, in 2016, ProZyme, Inc. launched Gly-Q Glycan Analysis System, an integrated platform that enables user-friendly and high-throughput glycoanalysis.

Related Press Release@ Glycomics Market Report

Glycomics Market Report Highlights

Enzymes is expected to be the fastest-growing segment in the global glycobiology market due to its wide application scope in research & diagnostics and repetitive purchase of these products
In the application segment, drug discovery & development accounted for the largest revenue share in 2018 owing to high demand for personalized medicines and focus on novel drug development
North America led the global glycomics/glycobiology market in 2018 and is expected to continue its dominance during the forecast period
Presence of a large number of research laboratories and pharmaceutical and biotechnology companies in North America is the major factor driving the regional market
Europe is expected to register the highest CAGR from 2019 to 2026 due to rising number of pharmaceutical and biopharmaceutical companies in the region
Some of the key companies include Danaher; ProZyme; Shimadzu Corporation; Agilent Technologies; Bruker; Merck KGaA; Takara Bio, Inc.; New England Biolabs; ThermoFisher Scientific, Inc.; and Waters Corporation

FISH Probe Market Growth, Opportunities and Forecast To 2026 | Oxford Gene Technology; Mirus Bio LLC; Agilent Technologies; Perkin Elmer Inc.; Genemed Biotechnologies Inc.

The global Fluorescent In Situ Hybridization (Fish) Probe Market size is expected to reach USD 1.04 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 6.8% during the forecast period. Increasing global population prone to target diseases and demand for accurate and effective diagnostics of these diseases are the factors attributed to the growth. Increasing use of FISH probes in vitro diagnosis of various infectious diseases is expected to create growth opportunities in near future.

In addition, supportive government initiatives, rising healthcare expenditure and awareness pertaining to the benefits associated with FISH probe technique are expected to drive the market growth during forecast period. Furthermore, technological advancement in Chromogenic In Situ Hybridization (CISH) such as higher storage time for analyzed samples for long duration studies is expected to fuel the demand.

FISH is most commonly used for the detection of genetic diseases such as Angelman syndrome, Prader-Willi syndrome, chronic myelogenous leukemia, Down’s syndrome, Velocardiofacial syndrome, 22q13 deletion syndrome, acute lymphoblastic leukemia, and cri-du-chat. The genetic disease segment led the overall market in 2018. The probe does not require live cells and can quantify automatically as compared to the conventional cytogenetics, and is more convenient and effective. This factor is anticipated to propel the segment growth. According to a publication from the Centers for Disease Control and Prevention (CDC) in 2018, Down’s syndrome was the most common genetic disorders with almost one in every 700 new newborns affected by the disorder.

Related Press Release@ FISH Probe Market

FISH Probe Market Report Highlights

Companion diagnostics is expected to command the largest market share of end use segment. Used in personalized medicine, it includes medical decision, products, and practices based on patient’s genetic, clinical, and genomic information
In oncology, major companion diagnostics are based on the FISH owing to higher reliability, sensitivity, accuracy, and procedure reproducibility, which are less affected by analytical variables and tissue fixation as compared to immunohistochemistry
miRNA is expected to be the fastest growing RNA segment, driven by factors such as increasing R&D and extensive usage in cancer detection
Asia Pacific is expected to showcase lucrative growth over the forecast period due to rising per capita healthcare expenditure, improving healthcare facilities, and demand for IVD testing for disease detection
Increasing R&D activities pertaining to cancer diagnostics and investment by private and government sector into biotech industry in Asia Pacific are the factors responsible for the growth
Key players operating in the Fluorescent In Situ Hybridization (FISH) probe market include Oxford Gene Technology; Mirus Bio LLC; Agilent Technologies; Perkin Elmer Inc.; Genemed Biotechnologies Inc.; Horizon Diagnostics; BioDot Inc.; Sigma Aldrich; Life Science Technologies; GSP Research Institute Co., Ltd; Abnova Corporation; Biosearch Technologies; F Hoffman La Roche AG; Bio Care Medical LLC; EXIQON; and Affymetrix Panomics